Abstract：
UNASSIGNED: Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Monoclonal antibodies (mAbs) have shown efficacy in reducing MS relapse rates, disease progression, and brain lesion activity.
UNASSIGNED: This article reviews the literature on the use of mAbs for the treatment of MS, including their mechanisms of action, clinical trial data, safety profiles, and long-term outcomes. The review focuses on the three main categories of mAbs used in MS: alemtuzumab, natalizumab, and anti-CD20 drugs. A literature search was conducted using relevant keywords and guidelines and reports from regulatory agencies were reviewed. The search covered studies published from inception to 31 December 202231 December 2022. The article also discusses the potential risks and benefits of these therapies, including their effects on infection rates, malignancies, and vaccination efficacy.
UNASSIGNED: Monoclonal antibodies have revolutionized the treatment of MS, but safety concerns must be considered, particularly with regards to infection rates, malignancy risk, and vaccination efficacy. Clinicians must weigh the potential benefits and risks of mAbs on an individual patient basis, taking into account factors such as age, disease severity, and comorbidities. Ongoing monitoring and surveillance are essential to ensure the long-term safety and effectiveness of monoclonal antibody therapies in MS.
UNASSIGNED: This article reviews the literature on the use of mAbs for the treatment of MS, including their mechanisms of action, clinical trial data, safety profiles, and long-term outcomes. The review focuses on the three main categories of mAbs used in MS: alemtuzumab, natalizumab, and anti-CD20 drugs. A literature search was conducted using relevant keywords and guidelines and reports from regulatory agencies were reviewed. The search covered studies published from inception to 31 December 202231 December 2022. The article also discusses the potential risks and benefits of these therapies, including their effects on infection rates, malignancies, and vaccination efficacy.
UNASSIGNED: Monoclonal antibodies have revolutionized the treatment of MS, but safety concerns must be considered, particularly with regards to infection rates, malignancy risk, and vaccination efficacy. Clinicians must weigh the potential benefits and risks of mAbs on an individual patient basis, taking into account factors such as age, disease severity, and comorbidities. Ongoing monitoring and surveillance are essential to ensure the long-term safety and effectiveness of monoclonal antibody therapies in MS.
摘要：
■多发性硬化症（MS）是一种影响中枢神经系统的自身免疫性疾病。单克隆抗体（mAb）已显示出降低MS复发率的功效，疾病进展,和脑部病变活动。
■本文回顾了有关使用单克隆抗体治疗MS的文献，包括他们的行动机制，临床试验数据,安全概况,和长期结果。该综述集中在MS中使用的单克隆抗体的三个主要类别：阿仑单抗，那他珠单抗,和抗CD20药物。使用相关关键词和指南进行了文献检索，并审查了监管机构的报告。搜索涵盖了从开始到2022年12月31日发表的研究。本文还讨论了这些疗法的潜在风险和益处，包括它们对感染率的影响，恶性肿瘤,和疫苗接种功效。
■单克隆抗体彻底改变了MS的治疗方法，但是必须考虑安全问题，特别是在感染率方面，恶性肿瘤风险，和疫苗接种功效。临床医生必须在个体患者的基础上权衡单克隆抗体的潜在益处和风险。考虑到年龄等因素，疾病严重程度,和合并症。持续的监测和监视对于确保MS中单克隆抗体疗法的长期安全性和有效性至关重要。
■本文回顾了有关使用单克隆抗体治疗MS的文献，包括他们的行动机制，临床试验数据,安全概况,和长期结果。该综述集中在MS中使用的单克隆抗体的三个主要类别：阿仑单抗，那他珠单抗,和抗CD20药物。使用相关关键词和指南进行了文献检索，并审查了监管机构的报告。搜索涵盖了从开始到2022年12月31日发表的研究。本文还讨论了这些疗法的潜在风险和益处，包括它们对感染率的影响，恶性肿瘤,和疫苗接种功效。
■单克隆抗体彻底改变了MS的治疗方法，但是必须考虑安全问题，特别是在感染率方面，恶性肿瘤风险，和疫苗接种功效。临床医生必须在个体患者的基础上权衡单克隆抗体的潜在益处和风险。考虑到年龄等因素，疾病严重程度,和合并症。持续的监测和监视对于确保MS中单克隆抗体疗法的长期安全性和有效性至关重要。
